Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2000 Oct;76(900):602–610. doi: 10.1136/pmj.76.900.602

Pharmacological treatment of Parkinson's disease

A Munchau 1, K Bhatia 1
PMCID: PMC1741769  PMID: 11009573

Full Text

The Full Text of this article is available as a PDF (133.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler C. H., Sethi K. D., Hauser R. A., Davis T. L., Hammerstad J. P., Bertoni J., Taylor R. L., Sanchez-Ramos J., O'Brien C. F. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology. 1997 Aug;49(2):393–399. doi: 10.1212/wnl.49.2.393. [DOI] [PubMed] [Google Scholar]
  2. Agid Y. Levodopa: is toxicity a myth? Neurology. 1998 Apr;50(4):858–863. doi: 10.1212/wnl.50.4.858. [DOI] [PubMed] [Google Scholar]
  3. Baas H., Beiske A. G., Ghika J., Jackson M., Oertel W. H., Poewe W., Ransmayr G. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):421–428. doi: 10.1136/jnnp.63.4.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bailey E. V., Stone T. W. The mechanism of action of amantadine in Parkinsonism: a review. Arch Int Pharmacodyn Ther. 1975 Aug;216(2):246–262. [PubMed] [Google Scholar]
  5. Basma A. N., Morris E. J., Nicklas W. J., Geller H. M. L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation. J Neurochem. 1995 Feb;64(2):825–832. doi: 10.1046/j.1471-4159.1995.64020825.x. [DOI] [PubMed] [Google Scholar]
  6. Ben-Shlomo Y., Churchyard A., Head J., Hurwitz B., Overstall P., Ockelford J., Lees A. J. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ. 1998 Apr 18;316(7139):1191–1196. doi: 10.1136/bmj.316.7139.1191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chase T. N., Engber T. M., Mouradian M. M. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol. 1996;69:497–501. [PubMed] [Google Scholar]
  8. Chiueh C. C., Wu R. M., Mohanakumar K. P., Sternberger L. M., Krishna G., Obata T., Murphy D. L. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann N Y Acad Sci. 1994 Nov 17;738:25–36. doi: 10.1111/j.1749-6632.1994.tb21786.x. [DOI] [PubMed] [Google Scholar]
  9. Churchyard A., Mathias C. J., Boonkongchuen P., Lees A. J. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997 Aug;63(2):228–234. doi: 10.1136/jnnp.63.2.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cotzias G. C., Papavasiliou P. S., Fehling C., Kaufman B., Mena I. Similarities between neurologic effects of L-dipa and of apomorphine. N Engl J Med. 1970 Jan 1;282(1):31–33. doi: 10.1056/NEJM197001012820107. [DOI] [PubMed] [Google Scholar]
  11. Del Dotto P., Colzi A., Musatti E., Strolin Benedetti M., Persiani S., Fariello R., Bonuccelli U. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease. Clin Neuropharmacol. 1997 Oct;20(5):455–465. doi: 10.1097/00002826-199710000-00011. [DOI] [PubMed] [Google Scholar]
  12. Djaldetti R., Baron J., Ziv I., Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology. 1996 Apr;46(4):1051–1054. doi: 10.1212/wnl.46.4.1051. [DOI] [PubMed] [Google Scholar]
  13. Duvoisin R. C. Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol. 1967 Aug;17(2):124–136. doi: 10.1001/archneur.1967.00470260014002. [DOI] [PubMed] [Google Scholar]
  14. Ebadi M., Srinivasan S. K., Baxi M. D. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol. 1996 Jan;48(1):1–19. doi: 10.1016/0301-0082(95)00029-1. [DOI] [PubMed] [Google Scholar]
  15. Factor S. A., Friedman J. H. The emerging role of clozapine in the treatment of movement disorders. Mov Disord. 1997 Jul;12(4):483–496. doi: 10.1002/mds.870120403. [DOI] [PubMed] [Google Scholar]
  16. Factor S. A., Molho E. S., Podskalny G. D., Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol. 1995;65:115–138. [PubMed] [Google Scholar]
  17. Fahn S. Is levodopa toxic? Neurology. 1996 Dec;47(6 Suppl 3):S184–S195. doi: 10.1212/wnl.47.6_suppl_3.184s. [DOI] [PubMed] [Google Scholar]
  18. Frankel J. P., Lees A. J., Kempster P. A., Stern G. M. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):96–101. doi: 10.1136/jnnp.53.2.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Friedman J. H., Goldstein S., Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol. 1998 Sep-Oct;21(5):285–288. [PubMed] [Google Scholar]
  20. Friedman J. H., Lannon M. C. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology. 1989 Sep;39(9):1219–1221. doi: 10.1212/wnl.39.9.1219. [DOI] [PubMed] [Google Scholar]
  21. Goetz C. G., Tanner C. M., Glantz R. H., Klawans H. L. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology. 1985 May;35(5):749–751. doi: 10.1212/wnl.35.5.749. [DOI] [PubMed] [Google Scholar]
  22. Graham D. G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol. 1978 Jul;14(4):633–643. [PubMed] [Google Scholar]
  23. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology. 1997 Oct;49(4):1060–1065. doi: 10.1212/wnl.49.4.1060. [DOI] [PubMed] [Google Scholar]
  24. Heikkila R. E., Manzino L., Cabbat F. S., Duvoisin R. C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 1984 Oct 4;311(5985):467–469. doi: 10.1038/311467a0. [DOI] [PubMed] [Google Scholar]
  25. Hely M. A., Morris J. G., Reid W. G., O'Sullivan D. J., Williamson P. M., Rail D., Broe G. A., Margrie S. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):903–910. doi: 10.1136/jnnp.57.8.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hobson D. E., Pourcher E., Martin W. R. Ropinirole and pramipexole, the new agonists. Can J Neurol Sci. 1999 Aug;26 (Suppl 2):S27–S33. doi: 10.1017/s0317167100000068. [DOI] [PubMed] [Google Scholar]
  27. Holm K. J., Spencer C. M. Entacapone. A review of its use in Parkinson's disease. Drugs. 1999 Jul;58(1):159–177. doi: 10.2165/00003495-199958010-00017. [DOI] [PubMed] [Google Scholar]
  28. Hughes A. J., Bishop S., Lees A. J., Stern G. M., Webster R., Bovingdon M. Rectal apomorphine in Parkinson's disease. Lancet. 1991 Jan 12;337(8733):118–118. doi: 10.1016/0140-6736(91)90780-s. [DOI] [PubMed] [Google Scholar]
  29. Hughes A. J., Daniel S. E., Kilford L., Lees A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–184. doi: 10.1136/jnnp.55.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Hughes A. J., Daniel S. E., Lees A. J. The clinical features of Parkinson's disease in 100 histologically proven cases. Adv Neurol. 1993;60:595–599. [PubMed] [Google Scholar]
  31. Kaakkola S., Gordin A., Männistö P. T. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol. 1994 Sep;25(5):813–824. doi: 10.1016/0306-3623(94)90082-5. [DOI] [PubMed] [Google Scholar]
  32. Kapoor R., Turjanski N., Frankel J., Kleedorfer B., Lees A., Stern G., Bovingdon M., Webster R. Intranasal apomorphine: a new treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990 Nov;53(11):1015–1015. doi: 10.1136/jnnp.53.11.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Keränen T., Gordin A., Harjola V. P., Karlsson M., Korpela K., Pentikäinen P. J., Rita H., Seppälä L., Wikberg T. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol. 1993 Apr;16(2):145–156. doi: 10.1097/00002826-199304000-00007. [DOI] [PubMed] [Google Scholar]
  34. Koller W. C., Pahwa R. Treating motor fluctuations with controlled-release levodopa preparations. Neurology. 1994 Jul;44(7 Suppl 6):S23–S28. [PubMed] [Google Scholar]
  35. Korczyn A. D., Brooks D. J., Brunt E. R., Poewe W. H., Rascol O., Stocchi F. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord. 1998 Jan;13(1):46–51. doi: 10.1002/mds.870130112. [DOI] [PubMed] [Google Scholar]
  36. Kornhuber J., Bormann J., Hübers M., Rusche K., Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol. 1991 Apr 25;206(4):297–300. doi: 10.1016/0922-4106(91)90113-v. [DOI] [PubMed] [Google Scholar]
  37. Kornhuber J., Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry. 1997 Jan 15;41(2):135–144. doi: 10.1016/S0006-3223(96)00047-9. [DOI] [PubMed] [Google Scholar]
  38. Kurth M. C., Adler C. H. COMT inhibition: a new treatment strategy for Parkinson's disease. Neurology. 1998 May;50(5 Suppl 5):S3–14. doi: 10.1212/wnl.50.5_suppl_5.s3. [DOI] [PubMed] [Google Scholar]
  39. Kurth M. C., Adler C. H., Hilaire M. S., Singer C., Waters C., LeWitt P., Chernik D. A., Dorflinger E. E., Yoo K. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology. 1997 Jan;48(1):81–87. doi: 10.1212/wnl.48.1.81. [DOI] [PubMed] [Google Scholar]
  40. Landau W. M. Clinical neuromythology IX. Pyramid sale in the bucket shop: DATATOP bottoms out. Neurology. 1990 Sep;40(9):1337–1339. doi: 10.1212/wnl.40.9.1337. [DOI] [PubMed] [Google Scholar]
  41. Lang A. E., Lozano A. M. Parkinson's disease. Second of two parts. N Engl J Med. 1998 Oct 15;339(16):1130–1143. doi: 10.1056/NEJM199810153391607. [DOI] [PubMed] [Google Scholar]
  42. Lees A. J. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ. 1995 Dec 16;311(7020):1602–1607. doi: 10.1136/bmj.311.7020.1602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Lees A. J., Montastruc J. L., Turjanski N., Rascol O., Kleedorfer B., Peyro Saint-Paul H., Stern G. M., Rascol A. Sublingual apomorphine and Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989 Dec;52(12):1440–1440. doi: 10.1136/jnnp.52.12.1440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Lesser R. P., Fahn S., Snider S. R., Cote L. J., Isgreen W. P., Barrett R. E. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology. 1979 Sep;29(9 Pt 1):1253–1260. doi: 10.1212/wnl.29.9_part_1.1253. [DOI] [PubMed] [Google Scholar]
  45. Lieberman A., Olanow C. W., Sethi K., Swanson P., Waters C. H., Fahn S., Hurtig H., Yahr M. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology. 1998 Oct;51(4):1057–1062. doi: 10.1212/wnl.51.4.1057. [DOI] [PubMed] [Google Scholar]
  46. Litvan I. Progressive supranuclear palsy and corticobasal degeneration. Baillieres Clin Neurol. 1997 Apr;6(1):167–185. [PubMed] [Google Scholar]
  47. MacMahon D. G., Sachdev D., Boddie H. G., Ellis C. J., Kendal B. R., Blackburn N. A. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990 Mar;53(3):220–223. doi: 10.1136/jnnp.53.3.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Marsden C. D., Parkes J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296. doi: 10.1016/s0140-6736(76)91416-1. [DOI] [PubMed] [Google Scholar]
  49. Marsden C. D. Parkinson's disease. Lancet. 1990 Apr 21;335(8695):948–952. doi: 10.1016/0140-6736(90)91006-v. [DOI] [PubMed] [Google Scholar]
  50. Marti-Massó J. F., Poza J. J., Lopez de Munain A. Drugs inducing or aggravating parkinsonism: a review. Therapie. 1996 Sep-Oct;51(5):568–577. [PubMed] [Google Scholar]
  51. Mena M. A., Pardo B., Casarejos M. J., Fahn S., García de Yébenes J. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord. 1992;7(1):23–31. doi: 10.1002/mds.870070105. [DOI] [PubMed] [Google Scholar]
  52. Miyawaki E., Meah Y., Koller W. C. Serotonin, dopamine, and motor effects in Parkinson's disease. Clin Neuropharmacol. 1997 Aug;20(4):300–310. doi: 10.1097/00002826-199708000-00002. [DOI] [PubMed] [Google Scholar]
  53. Mizuno Y., Kondo T., Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology. 1995 Mar;45(3 Suppl 3):S13–S21. doi: 10.1212/wnl.45.3_suppl_3.s13. [DOI] [PubMed] [Google Scholar]
  54. Montastruc J. L., Rascol O., Senard J. M., Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry. 1994 Sep;57(9):1034–1038. doi: 10.1136/jnnp.57.9.1034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Montastruc J. L., Rascol O., Senard J. M. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord. 1999 Sep;14(5):725–730. doi: 10.1002/1531-8257(199909)14:5<725::aid-mds1003>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  56. Nissenbaum H., Quinn N. P., Brown R. G., Toone B., Gotham A. M., Marsden C. D. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med. 1987 Nov;17(4):899–904. doi: 10.1017/s0033291700000702. [DOI] [PubMed] [Google Scholar]
  57. Nutt J. G., Woodward W. R., Beckner R. M., Stone C. K., Berggren K., Carter J. H., Gancher S. T., Hammerstad J. P., Gordin A. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994 May;44(5):913–919. doi: 10.1212/wnl.44.5.913. [DOI] [PubMed] [Google Scholar]
  58. Nutt J. G., Woodward W. R., Hammerstad J. P., Carter J. H., Anderson J. L. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med. 1984 Feb 23;310(8):483–488. doi: 10.1056/NEJM198402233100802. [DOI] [PubMed] [Google Scholar]
  59. Ogawa N., Kanazawa I., Kowa H., Kuno S., Mizuno Y., Tashiro K., Yanagisawa N. Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up. Eur Neurol. 1997;38 (Suppl 2):37–49. doi: 10.1159/000113482. [DOI] [PubMed] [Google Scholar]
  60. Olanow C. W., Myllylä V. V., Sotaniemi K. A., Larsen J. P., Pålhagen S., Przuntek H., Heinonen E. H., Kilkku O., Lammintausta R., Mäki-Ikola O. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology. 1998 Sep;51(3):825–830. doi: 10.1212/wnl.51.3.825. [DOI] [PubMed] [Google Scholar]
  61. Ostergaard L., Werdelin L., Odin P., Lindvall O., Dupont E., Christensen P. B., Boisen E., Jensen N. B., Ingwersen S. H., Schmiegelow M. Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995 Jun;58(6):681–687. doi: 10.1136/jnnp.58.6.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Pacchetti C., Albani G., Martignoni E., Godi L., Alfonsi E., Nappi G. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord. 1995 May;10(3):333–336. doi: 10.1002/mds.870100317. [DOI] [PubMed] [Google Scholar]
  63. Pahwa R., Lyons K., McGuire D., Silverstein P., Zwiebel F., Robischon M., Koller W. C. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Mov Disord. 1997 Sep;12(5):677–681. doi: 10.1002/mds.870120508. [DOI] [PubMed] [Google Scholar]
  64. Pezzoli G., Canesi M., Pesenti A., Mariani C. B. Pergolide mesylate in Parkinson's disease treatment. J Neural Transm Suppl. 1995;45:203–212. [PubMed] [Google Scholar]
  65. Piercey M. F., Hoffmann W. E., Smith M. W., Hyslop D. K. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol. 1996 Sep 19;312(1):35–44. doi: 10.1016/0014-2999(96)00454-2. [DOI] [PubMed] [Google Scholar]
  66. Pincus J. H., Barry K. Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods. Neurology. 1988 Mar;38(3):481–483. doi: 10.1212/wnl.38.3.481. [DOI] [PubMed] [Google Scholar]
  67. Pondal M., Del Ser T., Bermejo F. Anticholinergic therapy and dementia in patients with Parkinson's disease. J Neurol. 1996 Jul;243(7):543–546. doi: 10.1007/BF00886877. [DOI] [PubMed] [Google Scholar]
  68. Quinn N., Critchley P., Marsden C. D. Young onset Parkinson's disease. Mov Disord. 1987;2(2):73–91. doi: 10.1002/mds.870020201. [DOI] [PubMed] [Google Scholar]
  69. Quinn N. Drug treatment of Parkinson's disease. BMJ. 1995 Mar 4;310(6979):575–579. doi: 10.1136/bmj.310.6979.575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Quinn N., Marsden C. D. Lithium for painful dystonia in Parkinson's disease. Lancet. 1986 Jun 14;1(8494):1377–1377. doi: 10.1016/s0140-6736(86)91681-8. [DOI] [PubMed] [Google Scholar]
  71. Quinn N., Parkes D., Janota I., Marsden C. D. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord. 1986;1(1):65–68. doi: 10.1002/mds.870010109. [DOI] [PubMed] [Google Scholar]
  72. Rajput A. H., Fenton M. e., Birdi S., Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord. 1997 Sep;12(5):634–638. doi: 10.1002/mds.870120503. [DOI] [PubMed] [Google Scholar]
  73. Rajput A. H., Offord K., Beard C. M., Kurland L. T. Epidemiological survey of dementia in parkinsonism and control population. Adv Neurol. 1984;40:229–234. [PubMed] [Google Scholar]
  74. Rajput A. H., Rozdilsky B., Rajput A. Accuracy of clinical diagnosis in parkinsonism--a prospective study. Can J Neurol Sci. 1991 Aug;18(3):275–278. doi: 10.1017/s0317167100031814. [DOI] [PubMed] [Google Scholar]
  75. Rascol O., Brooks D. J., Brunt E. R., Korczyn A. D., Poewe W. H., Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord. 1998 Jan;13(1):39–45. doi: 10.1002/mds.870130111. [DOI] [PubMed] [Google Scholar]
  76. Rascol O., Lees A. J., Senard J. M., Pirtosek Z., Montastruc J. L., Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol. 1996 Jun;19(3):234–245. doi: 10.1097/00002826-199619030-00005. [DOI] [PubMed] [Google Scholar]
  77. Richard I. H., Kurlan R., Tanner C., Factor S., Hubble J., Suchowersky O., Waters C. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology. 1997 Apr;48(4):1070–1077. doi: 10.1212/wnl.48.4.1070. [DOI] [PubMed] [Google Scholar]
  78. Riley D. E., Lang A. E. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology. 1993 Aug;43(8):1459–1464. doi: 10.1212/wnl.43.8.1459. [DOI] [PubMed] [Google Scholar]
  79. Rinne U. K., Bracco F., Chouza C., Dupont E., Gershanik O., Marti Masso J. F., Montastruc J. L., Marsden C. D., Dubini A., Orlando N. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology. 1997 Feb;48(2):363–368. doi: 10.1212/wnl.48.2.363. [DOI] [PubMed] [Google Scholar]
  80. Rinne U. K., Larsen J. P., Siden A., Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology. 1998 Nov;51(5):1309–1314. doi: 10.1212/wnl.51.5.1309. [DOI] [PubMed] [Google Scholar]
  81. Rinne U. K. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology. 1989 Mar;39(3):336–339. doi: 10.1212/wnl.39.3.336. [DOI] [PubMed] [Google Scholar]
  82. Roberts J. W., Cora-Locatelli G., Bravi D., Amantea M. A., Mouradian M. M., Chase T. N. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology. 1993 Dec;43(12):2685–2688. doi: 10.1212/wnl.43.12.2685. [DOI] [PubMed] [Google Scholar]
  83. Ruottinen H. M., Rinne U. K. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol. 1996 Aug;19(4):283–296. doi: 10.1097/00002826-199619040-00001. [DOI] [PubMed] [Google Scholar]
  84. Ruottinen H. M., Rinne U. K. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):36–40. doi: 10.1136/jnnp.60.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. SCHWAB R. S., AMADOR L. V., LETTVIN J. Y. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc. 1951;56:251–253. [PubMed] [Google Scholar]
  86. SHY G. M., DRAGER G. A. A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. Arch Neurol. 1960 May;2:511–527. doi: 10.1001/archneur.1960.03840110025004. [DOI] [PubMed] [Google Scholar]
  87. STEELE J. C., RICHARDSON J. C., OLSZEWSKI J. PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA. Arch Neurol. 1964 Apr;10:333–359. doi: 10.1001/archneur.1964.00460160003001. [DOI] [PubMed] [Google Scholar]
  88. Schrag A., Ben-Shlomo Y., Brown R., Marsden C. D., Quinn N. Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality. Mov Disord. 1998 Nov;13(6):885–894. doi: 10.1002/mds.870130605. [DOI] [PubMed] [Google Scholar]
  89. Schwab R. S., England A. C., Jr, Poskanzer D. C., Young R. R. Amantadine in the treatment of Parkinson's disease. JAMA. 1969 May 19;208(7):1168–1170. [PubMed] [Google Scholar]
  90. Schwarz J., Scheidtmann K., Trenkwalder C. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa. Eur Neurol. 1997;37(4):236–238. doi: 10.1159/000117449. [DOI] [PubMed] [Google Scholar]
  91. Silva M. A., Mattern C., Häcker R., Tomaz C., Huston J. P., Schwarting R. K. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. Synapse. 1997 Dec;27(4):294–302. doi: 10.1002/(SICI)1098-2396(199712)27:4<294::AID-SYN3>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  92. Soykan I., Sarosiek I., Shifflett J., Wooten G. F., McCallum R. W. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord. 1997 Nov;12(6):952–957. doi: 10.1002/mds.870120618. [DOI] [PubMed] [Google Scholar]
  93. Stibe C. M., Lees A. J., Kempster P. A., Stern G. M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988 Feb 20;1(8582):403–406. doi: 10.1016/s0140-6736(88)91193-2. [DOI] [PubMed] [Google Scholar]
  94. Uitti R. J., Rajput A. H., Ahlskog J. E., Offord K. P., Schroeder D. R., Ho M. M., Prasad M., Rajput A., Basran P. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology. 1996 Jun;46(6):1551–1556. doi: 10.1212/wnl.46.6.1551. [DOI] [PubMed] [Google Scholar]
  95. Verhagen Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M. M., Chase T. N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 1998 May;50(5):1323–1326. doi: 10.1212/wnl.50.5.1323. [DOI] [PubMed] [Google Scholar]
  96. Weiner W. J., Factor S. A., Sanchez-Ramos J. R., Singer C., Sheldon C., Cornelius L., Ingenito A. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology. 1993 Jan;43(1):21–27. doi: 10.1212/wnl.43.1_part_1.21. [DOI] [PubMed] [Google Scholar]
  97. Weiner W. J. The initial treatment of Parkinson's disease should begin with levodopa. Mov Disord. 1999 Sep;14(5):716–724. doi: 10.1002/1531-8257(199909)14:5<716::aid-mds1002>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  98. Wenning G. K., Ben Shlomo Y., Magalhães M., Daniel S. E., Quinn N. P. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 1994 Aug;117(Pt 4):835–845. doi: 10.1093/brain/117.4.835. [DOI] [PubMed] [Google Scholar]
  99. Wolters E. C., Jansen E. N., Tuynman-Qua H. G., Bergmans P. L. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 1996 Oct;47(4):1085–1087. doi: 10.1212/wnl.47.4.1085. [DOI] [PubMed] [Google Scholar]
  100. Yoshikawa T., Minamiyama Y., Naito Y., Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem. 1994 Mar;62(3):1034–1038. doi: 10.1046/j.1471-4159.1994.62031034.x. [DOI] [PubMed] [Google Scholar]
  101. Zappia M., Montesanti R., Colao R., Branca D., Nicoletti G., Aguglia U., Quattrone A. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. Mov Disord. 1997 Jan;12(1):103–106. doi: 10.1002/mds.870120118. [DOI] [PubMed] [Google Scholar]
  102. Ziv I., Melamed E. Role of apoptosis in the pathogenesis of Parkinson's disease: A novel therapeutic opportunity? Mov Disord. 1998 Nov;13(6):865–870. doi: 10.1002/mds.870130602. [DOI] [PubMed] [Google Scholar]
  103. Zoldan J., Friedberg G., Weizman A., Melamed E. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Adv Neurol. 1996;69:541–544. [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES